Mphasis Strong FY26 Performance Driven by Record AI-Led Wins

Mphasis announced strong results for the quarter and financial year ended March 31, 2026. The company reported a 11.6% YoY revenue growth for the full year and a 14.4% YoY revenue increase in Q4 FY26. Driven by strong demand for AI-led solutions, the company achieved record New TCV wins of USD 2.1 billion for the year. Additionally, the Board recommended a final dividend of ₹62 per equity share.

Financial Highlights for FY26

Mphasis concluded the financial year ending March 31, 2026, with robust growth metrics. Full-year revenue grew by 11.6% YoY on a reported basis. Operating margin for the year stood at 15.3%. The company reported a consolidated net profit of ₹18,626.02 million for the financial year. The Board of Directors has recommended a final dividend of ₹62 per share of face value ₹10, pending shareholder approval at the upcoming Annual General Meeting.

Q4 FY26 Performance

In the fourth quarter, Mphasis recorded strong momentum with revenue growing 6.0% QoQ and 14.4% YoY. Operating margins showed improvement, growing 20 bps QoQ to 15.4%. The EPS before exceptional items reached ₹26.7, marking an 8.6% QoQ and 13.7% YoY increase.

Strategic Growth and AI Adoption

A key driver for the company’s success this year has been the rapid adoption of its AI-led propositions. Mphasis secured New TCV wins totaling USD 2.1 billion in FY26, with 60% being AI-led. In the fourth quarter alone, TCV wins amounted to USD 407 million, with 64% attributed to AI-led projects. The company continues to invest in its NeoIP™ suite and recently completed the acquisition of Theory and Practice (TAP) to enhance its decision intelligence capabilities.

Leadership and Governance

The Board of Directors has approved the re-appointment of Mr. Nitin Rakesh as Chief Executive Officer and Managing Director for a term of five consecutive years, effective October 1, 2026. Additionally, Ms. Maureen Anne Erasmus has been re-appointed as an Independent Director for a second and final term of five years, effective December 20, 2026. The 35th Annual General Meeting is scheduled to be held on July 23, 2026.

Source: BSE

Previous Article

AstraZeneca Pharma India Limited Confirmation of Security Dematerialization Compliance

Next Article

Mphasis Accelerated Growth and Strong AI-Led Performance in FY26